Samsung Biologics Co.,Ltd. (207940.KS)
KRW 959000.0
(-2.14%)
KRW 959000.0
(-2.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1603.46 Billion KRW | 23.38% |
| 2022 | 1354.09 Billion KRW | 85.37% |
| 2021 | 723.92 Billion KRW | 71.78% |
| 2020 | 443.02 Billion KRW | 37.53% |
| 2019 | 240.65 Billion KRW | -23.67% |
| 2018 | 410.26 Billion KRW | 2094.85% |
| 2017 | -40.38 Billion KRW | 119.2% |
| 2016 | -22.27 Billion KRW | -102.24% |
| 2015 | 2532.34 Billion KRW | 6315.36% |
| 2014 | -70.86 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 434.51 Billion KRW | 55.46% |
| 2024 Q3 | 338.57 Billion KRW | -45.51% |
| 2024 Q1 | 221.29 Billion KRW | -18.75% |
| 2023 Q1 | 319.76 Billion KRW | -39.05% |
| 2023 Q3 | 501.81 Billion KRW | 17.48% |
| 2023 Q2 | 427.14 Billion KRW | 33.58% |
| 2023 Q4 | 514.72 Billion KRW | 2.57% |
| 2023 FY | - KRW | 23.38% |
| 2022 Q2 | 312.33 Billion KRW | 29.81% |
| 2022 FY | - KRW | 85.37% |
| 2022 Q4 | 524.61 Billion KRW | 77.58% |
| 2022 Q3 | 295.42 Billion KRW | -5.42% |
| 2022 Q1 | 240.61 Billion KRW | 49.8% |
| 2021 Q2 | 217.24 Billion KRW | 79.32% |
| 2021 FY | - KRW | 71.78% |
| 2021 Q4 | 160.61 Billion KRW | -33.53% |
| 2021 Q3 | 241.65 Billion KRW | 11.23% |
| 2021 Q1 | 121.15 Billion KRW | 0.59% |
| 2020 Q4 | 120.44 Billion KRW | 3.68% |
| 2020 Q3 | 116.17 Billion KRW | 7.76% |
| 2020 Q1 | 86.73 Billion KRW | -58.32% |
| 2020 FY | - KRW | 37.53% |
| 2020 Q2 | 107.81 Billion KRW | 24.29% |
| 2019 Q1 | 2.45 Billion KRW | -99.43% |
| 2019 FY | - KRW | -23.67% |
| 2019 Q4 | 208.09 Billion KRW | 150.91% |
| 2019 Q3 | 82.93 Billion KRW | 314.21% |
| 2019 Q2 | 20.02 Billion KRW | 716.85% |
| 2018 Q2 | -11.02 Billion KRW | 60.02% |
| 2018 FY | - KRW | 2094.85% |
| 2018 Q4 | 433.45 Billion KRW | 2533.62% |
| 2018 Q3 | -17.81 Billion KRW | -61.49% |
| 2018 Q1 | -27.58 Billion KRW | -179.99% |
| 2017 Q4 | 34.49 Billion KRW | 127.27% |
| 2017 Q1 | -34.73 Billion KRW | -6.69% |
| 2017 FY | - KRW | 119.2% |
| 2017 Q2 | -25.75 Billion KRW | 25.84% |
| 2017 Q3 | 15.17 Billion KRW | 158.92% |
| 2016 Q3 | -36.57 Billion KRW | -26.54% |
| 2016 Q2 | -28.9 Billion KRW | -15.8% |
| 2016 Q4 | -32.55 Billion KRW | 10.99% |
| 2016 Q1 | -24.96 Billion KRW | 0.0% |
| 2016 FY | - KRW | -102.24% |
| 2015 FY | - KRW | 6315.36% |
| 2014 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | -10134.618% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | -2298.906% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | -1360.213% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -18897.581% |
| Green Cross Corporation | 109.81 Billion KRW | -1360.213% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 2617.26% |
| Celltrion, Inc. | 897.26 Billion KRW | -78.706% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | -6939.849% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 7321.256% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 5264.537% |